English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 13 September 2022, 7:40 JST

Source: PT Bio Farma (Persero)
Indonesia's Bio Farma ready to produce IndoVac Covid-19 vaccines
Global markets in view for the shariah-compliant IndoVac vaccine brand

BANDUNG, INDONESIA, Sept 13, 2022 - (JCN Newswire) - PT Bio Farma, the holding company for state-owned pharmaceutical companies in Indonesia, announced a milestone in manufacturing IndoVac, its Covid-19 vaccine brand which includes primary series vaccines, booster vaccines and vaccines for children, in development since November 2021.

IndoVac Covid-19 vaccine in production at PT Bio Farma's facilities near Bandung, Indonesia (Image: PT Bio Farma)

Honesti Baasyir, President Director of Bio Farma, said the company collaborated with Baylor College of Medicine, a private, independent health sciences center in Houston, Texas to develop IndoVac, a recombinant protein subunit vaccine produced from yeast.

According to Honesti, "IndoVac uses vaccine technology platforms which are compatible with our equipment and facilities. The technology platforms for protein recombinant vaccines offer other benefits as well; they can be adapted to new strains of Covid-19.

"Results from primary series Phase 1 and Phase 2 clinical trials show that IndoVac vaccines offer quality safety and efficacy, no less than other Covid-19 vaccines. Now we are completing the documentation to wrap up Phase 3."

Honesti said Bio Farma has had intense communication with the Indonesian Food and Drug Administration (BPOM) since July to provide necessary Phase 3 primary series data, so the BPOM can release an Emergency Use Authorization (EUA) permit for the vaccine. The EUA is the permit for medical supplies, including vaccines and medications, used during a public health emergency.

In Indonesia, BPOM plays the key role as a regulatory gatekeeper of medicines and vaccines used in the country. BPOM's head Penny K. Lukito, during a hearing at the Indonesian House of Representatives, said that the regulator expects to release the EUA for IndoVac's primary series vaccines in mid-September.

Shariah Compliant

Bio Farma has already processed the Halal certification (Shariah compliant) for the IndoVac primary series vaccine. The vaccine passed the audit by The Indonesian Ulema Council Food and Drug Analysis Agency (LPPOM MUI), which reviews the halal aspect of a product. The certificate from the Halal Certification Agency (BPJPH) of the Religious Affairs Ministry is expected to be released soon after the BPOM's EUA for IndoVac.

After securing all the necessary permits, Bio Farma will be ready to move on to the next stage, mass production of the vaccine. Bio Farma plans to produce an initial 20 million doses of primary series vaccine this year, which will be further increased to 40 million doses in 2023, as the company expands its production facilities. In 2024, production may further increase to 100 million doses per year, depending on market demand.

Booster Vaccine and Vaccine for Children

Bio Farma also initiated clinical trials for its booster vaccine on September 1. Bio Farma conducted these trials at the Hasan Sadikin General Hospital in Bandung (Faculty of Medicine, Padjajaran University) and Dr I.G.N.G Ngoerah General Hospital in Bali (Children's Health Sciences Dept, Udayana University). Trials involved 900 subjects aged 8 and above to test the booster vaccines. Next, the company plans to conduct clinical trials for children, following trial registration with the BPOM.

All Covid-19 vaccines made by Bio Farma, including the primary series vaccines, booster vaccines and vaccines for children, will be labelled IndoVac. Bio Farma started the process of registering the IndoVac brand name for Covid-19 vaccines at the Directorate General of Intellectual Property (DGIP) of the Ministry of Law and Human Rights on July 29.

President Joko Widodo gave the IndoVac name to the vaccine. "We are in the process of securing the name now. Should no-one object at this level, we will proceed to the next stage until we secure an IndoVac trade licence and patent from the ministry, as a product of Bio Farma," Honesti said.

Made-in-Indonesia Vaccines

Honesti said IndoVac is special, as one of the few made-in-Indonesia vaccine products, developed and manufactured by the nation's children. Bio Farma handles the manufacturing process from upstream to downstream. Locally sourced content in the IndoVac vaccines, according to Bio Farma, will be around 80%.

"This is a step closer to achieving independence in the health sector. With such a high proportion of local content, we expect to help reduce the nation's dependency on imported vaccines," Honesti said.

Bio Farma hopes to capture the export market with its IndoVac vaccines. "We will not only produce them to meet domestic needs, but for the supply of global markets," said Honesti. "We registered for EUL with the World Health Organization (WHO), so the vaccine can be used in other countries through the Covax Facility for multilateral procurement. (The EUL assesses and lists vaccines during emergencies in non-vaccine-producing countries.)

"With our Covid-19 vaccines, we hope to contribute to the health industry, not just in Indonesia, but in the world," said Honesti.

For Bio Farma, it's not the first experience with clinical trials, having conducted more than 30 trials, including for Covid-19, in Indonesia. Bio Farma also has experience in conducting clinical trials overseas, for Pentabio and Novel Oral Polio Vaccine type 2 (nOPV2).

Bio Farma's Success in Polio Vaccine

Honesti said apart from the Covid-19 primary series vaccines, Bio Farma previously secured EUA from BPOM and EUL from WHO for its novel Oral Polio Vaccine type 2 (nOPV2). As Indonesia hasn't had any polio outbreaks since 2014, it never used nOPV2. However, the Bio Farma-manufactured vaccine was used by countries in Africa, Europe and the Middle East.

Among the countries in Africa that have used Bio Farma's nOPV2's vaccine are Algeria, Cameroon, the Democratic Republic of Congo, Djibouti, Ethiopia, Gambia, Ghana, Nigeria, Senegal, and Uganda. In Europe, the vaccine was used in Ukraine and in the Middle East, it was used in Israel, Egypt, Somalia and Yemen.

In manufacturing the nOPV2 vaccine, Bio Farma collaborated with world-class institutions like Bill and Melinda Gates Foundation (BMGF), PATH and the WHO. Bio Farma has since become the main supplier of polio vaccines in the world, and currently contributes 67 percent to the global supply of polio vaccines. It distributes the vaccines via bilateral or multilateral means (through UNICEF).

Bio Farma's Laboratories have been internationally acknowledged as reference labs to check samples of polio viruses, while Bio Farma's success in producing and exporting nOPV2 vaccines shows the Indonesian state-owned company contributing to the world's health sector, apart from providing the necessary polio vaccine for domestic use at home in Indonesia.

Media Contact:
R. Rifa Herdian
PT Bio Farma (Persero)
Corporate Secretary & Investor Relations
Tel: +62-81-2542-8844
Email: rifaherdian@biofarma.co.id

Topic: Production report
Source: PT Bio Farma (Persero)

Sectors: Daily News, BioTech, Healthcare & Pharm, Regional, Local Biz, MedTech
From the Asia Corporate News Network

Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.


PT Bio Farma (Persero) Related News
Oct 4, 2022 07:00 HKT/SGT
Bio Farma secures Multi-year Purchase Contract from UNICEF for its novel Oral Polio Vaccine type 2 (nOPV2)
Sept 30, 2022 18:00 HKT/SGT
Bio Farma to Export its Polio Vaccine After Securing Purchase Contracts from UNICEF for 2022 and 2023
Sept 9, 2022 17:00 HKT/SGT
Indonesian pharmaceutical Bio Farma ready to produce IndoVac Covid-19 vaccines
May 1, 2015 14:00 HKT/SGT
9th International Conference on Typhoid, Invasive NTS Disease Held in Bali, Indonesia
Dec 9, 2014 13:00 HKT/SGT
Bio Farma Rolls Out Pentavalent Vaccine to All Provinces of Indonesia in 2014
More news >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575